过敏性疾病是一类常见病，发病率高达20%-30%，严重影响人类健康。目前对过敏性疾病的治疗方法主要是以避免接触过敏原及抗组胺药物为主的对症治疗，疗效不满意，急需寻找新的、更有效的治疗方法。调节性T细胞（Treg）在调控免疫反应、抑制过敏炎症中具有重要作用，然而如何诱导产生抗原特异性Treg并应用于临床治疗仍有待进一步研究。根据转化生长因子-β（TGFβ）可诱导调节性T细胞、抑制过敏反应的特点，前期研究中，我们构建了TGFβ/特异性抗原（卵蛋白；OVA）融合蛋白表达载体并对其免疫学特性进行了鉴定。本课题拟进一步构建TGFβ/OVA纳米疫苗，探讨这种纳米疫苗对过敏性鼻炎小鼠的抑制作用和作用机理。本研究完成后，可望为过敏性疾病的治疗提供一种新的思维方式；所构建的纳米疫苗经过后续的研究后，有望成为一种新的、有效的治疗过敏性疾病的靶向性免疫药物。

Allergic diseases are common in the world; its prevalence has reached 20%-30% and has significant negative impact on human health. The current therapies for allergic diseases include avoiding exposing to specific allergens and symptom control agents, such as anti-histamine; the therapeutic effect is unsatisfactory. Based on the fact that transforming growth factor (TGF)β can induce regulatory T cells and suppress allergic response, in the proposed study, we plan to construct a nano-vaccine carrying TGFb/OVA (a specific allergen); its inhibitory effect on allergic rhinitis will be tested with an animal model; the underlying mechanism will be investigated. Upon completion, the proposed study is expected to create a novel therapeutic strategy for allergic diseases. After performing the required tests, the TGFb/OVA nano-vaccine has the potential to be a novel, more effective anti-allergy agent.